Pfizer partnered with the U.S. government through TrumpRx to offer deep discounts on more than 30 medications, with the company positioned as the leading participant in the program. The TrumpRx ...

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

The U.S. Food and Drug Administration (FDA) is unlikely to renew the authorization granted to use Pfizer (NYSE:PFE) and BioNTech’s (BNTX) COVID-19 vaccine in young children this fall, The Guardian ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children under the age of 5 ahead of the peak season, according to multiple outlets.

PALO ALTO, Calif. (KGO) -- The FDA is waiting on more data before deciding to authorize Pfizer's COVID-19 vaccine for children under 5-years-old. "The great news was that it was safe for every kid, ...

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

Pfizer PFE is due to report third-quarter 2025 results on Nov. 4. All eyes will be on sales of Pfizer’s oncology drugs, which account for more than 25% of the company’s total revenues. Pfizer’s key ...